CMML
MCID: CHR285
MIFTS: 60

Chronic Myelomonocytic Leukemia (CMML)

Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Chronic Myelomonocytic Leukemia

MalaCards integrated aliases for Chronic Myelomonocytic Leukemia:

Name: Chronic Myelomonocytic Leukemia 12 74 52 58 36 29 6 15 37 17
Leukemia, Myelomonocytic, Chronic 52 71
Leukemia Myelomonocytic Chronic 54
Cmml 58

Characteristics:

Orphanet epidemiological data:

58
chronic myelomonocytic leukemia
Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0080188
KEGG 36 H02411
NCIt 49 C3178
ICD10 32 C93.1
MESH via Orphanet 44 D015477
ICD10 via Orphanet 33 C93.1
UMLS via Orphanet 72 C0023480
Orphanet 58 ORPHA98823
UMLS 71 C0023480

Summaries for Chronic Myelomonocytic Leukemia

KEGG : 36 Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder associated with peripheral blood monocytosis, with an inherent risk for leukemic transformation. CMML has overlapping features of myelodysplastic syndromes (MDS) [DS:H01481] and myeloproliferative neoplasms (MPN). Gene mutations are seen in >90% of patients, with common abnormalities involving; epigenetic regulators (TET2 -60% and ASXL1 -40%), spliceosome components (SRSF2 -50%), transcription factors (RUNX1 -15%) and cell signaling (RAS -30%, CBL -15%).

MalaCards based summary : Chronic Myelomonocytic Leukemia, also known as leukemia, myelomonocytic, chronic, is related to juvenile myelomonocytic leukemia and myelodysplastic/myeloproliferative neoplasm, and has symptoms including fatigue, fever and night sweats. An important gene associated with Chronic Myelomonocytic Leukemia is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are Ras signaling pathway and Developmental Biology. The drugs Cefepime and Mercaptopurine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.

Wikipedia : 74 Chronic myelomonocytic leukemia (CMML) is a type of leukemia, which are cancers of the blood-forming... more...

Related Diseases for Chronic Myelomonocytic Leukemia

Diseases in the Chronic Myelomonocytic Leukemia family:

Juvenile Myelomonocytic Leukemia

Diseases related to Chronic Myelomonocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 351)
# Related Disease Score Top Affiliating Genes
1 juvenile myelomonocytic leukemia 33.7 U2AF1 TET2 SETBP1 RUNX1 PTPN11 PDGFRB
2 myelodysplastic/myeloproliferative neoplasm 32.9 U2AF1 TET2 SRSF2 SETBP1 PTPN11 PDGFRB
3 myelodysplastic syndrome 32.6 U2AF1 TET2 SRSF2 SETBP1 RUNX1 PTPN11
4 refractory anemia 32.0 TET2 RUNX1 ASXL1
5 leukemia 31.9 U2AF1 TET2 RUNX1 PTPN11 NF1 KIT
6 thrombocytopenia 31.8 U2AF1 RUNX1 JAK2 GATA2 ETV6 CSF2
7 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 31.6 RUNX1 KIT FLT3 ETV6
8 acute leukemia 31.5 SETBP1 RUNX1 KIT JAK2 GATA2 FLT3
9 hypereosinophilic syndrome 31.5 PDGFRB KIT JAK2 CSF2
10 monocytic leukemia 31.5 RUNX1 FLT3 CSF2
11 neutropenia 31.5 PTPN11 FLT3 CSF3R CSF2
12 myeloid leukemia 31.5 U2AF1 TET2 RUNX1 PTPN11 KIT JAK2
13 pancytopenia 31.4 U2AF1 RUNX1 KIT FLT3 CSF2
14 mastocytosis 31.3 TET2 SRSF2 PTPN11 PDGFRB KIT JAK2
15 thrombocytosis 31.3 U2AF1 TET2 JAK2 CSF2 ASXL1
16 systemic mastocytosis 31.3 U2AF1 TET2 SRSF2 PTPN11 PDGFRB KIT
17 chronic neutrophilic leukemia 31.2 U2AF1 TET2 SRSF2 SETBP1 JAK2 CSF3R
18 myeloproliferative neoplasm 31.2 U2AF1 TET2 RUNX1 PTPN11 PDGFRB NF1
19 atypical chronic myeloid leukemia 31.1 U2AF1 TET2 SRSF2 SETBP1 RUNX1 PDGFRB
20 myeloid sarcoma 31.1 U2AF1 KIT FLT3
21 leukemia, acute myeloid 31.1 U2AF1 TET2 SRSF2 SETBP1 RUNX1 PTPN11
22 refractory cytopenia with multilineage dysplasia 31.1 U2AF1 TET2 SETBP1 GATA2 ASXL1
23 myelofibrosis 31.0 U2AF1 TET2 SRSF2 SETBP1 RUNX1 PDGFRB
24 essential thrombocythemia 31.0 U2AF1 TET2 PTPN11 KIT JAK2 EZH2
25 leukemia, chronic myeloid 30.9 U2AF1 SETBP1 RUNX1 PTPN11 PDGFRB NF1
26 myeloma, multiple 30.9 U2AF1 PTPN11 KIT JAK2 FLT3 EZH2
27 chronic leukemia 30.9 U2AF1 TET2 SRSF2 SETBP1 PDGFRB KIT
28 leukemia, acute lymphoblastic 3 30.8 RUNX1 FLT3 ETV6
29 megakaryocytic leukemia 30.8 U2AF1 RUNX1 JAK2 CSF2
30 acute promyelocytic leukemia 30.8 U2AF1 RUNX1 GATA2 FLT3 EZH2 ETV6
31 myeloproliferative disorder, chronic, with eosinophilia 30.8 PDGFRB ETV6
32 leukemia, chronic lymphocytic 30.8 U2AF1 TET2 SRSF2 PTPN11 KIT JAK2
33 polycythemia vera 30.7 U2AF1 TET2 PTPN11 PDGFRB KIT JAK2
34 leukemia, acute lymphoblastic 30.7 U2AF1 RUNX1 PTPN11 KIT JAK2 GATA2
35 sm-ahnmd 30.7 U2AF1 TET2 SRSF2 KIT JAK2 ASXL1
36 acute monoblastic leukemia 30.7 NF1 CSF2
37 severe congenital neutropenia 30.6 PTPN11 JAK2 FLT3 CSF3R CSF2
38 blood platelet disease 30.6 U2AF1 RUNX1 KIT JAK2 FLT3 CSF2
39 aplastic anemia 30.5 U2AF1 TET2 GATA2 FLT3 CSF3R CSF2
40 down syndrome 30.5 RUNX1 JAK2 FLT3 ETV6
41 lung cancer susceptibility 3 30.5 U2AF1 PDGFRB NF1 KIT EZH2 DNMT3A
42 hematologic cancer 30.4 U2AF1 RUNX1 PTPN11 PDGFRB KIT JAK2
43 pdgfrb-associated chronic eosinophilic leukemia 11.5
44 splenomegaly 10.7
45 primary hypereosinophilic syndrome 10.7 PDGFRB ETV6
46 mixed phenotype acute leukemia 10.7 U2AF1 SETBP1 DNMT3A
47 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.7 RUNX1 KIT FLT3
48 acute erythroid leukemia 10.6 JAK2 GATA2
49 systemic mastocytosis with associated hematologic neoplasm 10.6 TET2 SRSF2 KIT ASXL1
50 nephroma 10.6 U2AF1 KIT ETV6

Graphical network of the top 20 diseases related to Chronic Myelomonocytic Leukemia:



Diseases related to Chronic Myelomonocytic Leukemia

Symptoms & Phenotypes for Chronic Myelomonocytic Leukemia

UMLS symptoms related to Chronic Myelomonocytic Leukemia:


fatigue, fever, night sweats

GenomeRNAi Phenotypes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

26 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 10.05 EZH2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-118 10.05 PTPN11
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-121 10.05 PTPN11
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 10.05 SETBP1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-138 10.05 CSF2 PTPN11
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-149 10.05 PTPN11
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 10.05 SETBP1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 10.05 SETBP1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-170 10.05 CSF2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.05 CSF2 PTPN11
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 10.05 EZH2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 10.05 EZH2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-35 10.05 EZH2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-37 10.05 PTPN11
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.05 CSF2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-47 10.05 PTPN11
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-67 10.05 EZH2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.05 EZH2
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.05 EZH2
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-83 10.05 EZH2
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 10.05 SETBP1
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.05 SETBP1
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.05 CSF2
24 Decreased viability GR00106-A-0 9.78 U2AF1
25 Decreased viability GR00173-A 9.78 FLT3
26 Decreased viability GR00221-A-1 9.78 FLT3 KIT NF1 PDGFRB
27 Decreased viability GR00221-A-2 9.78 JAK2 NF1
28 Decreased viability GR00221-A-3 9.78 PDGFRB
29 Decreased viability GR00221-A-4 9.78 FLT3 NF1 PDGFRB
30 Decreased viability GR00249-S 9.78 CSF2 CSF3R NF1 RUNX1
31 Decreased viability GR00301-A 9.78 KIT
32 Decreased viability GR00342-S-1 9.78 PDGFRB
33 Decreased viability GR00381-A-1 9.78 HIP1
34 Decreased viability GR00386-A-1 9.78 EZH2 GATA2 KDM6A NF1 SRSF2
35 Decreased viability GR00402-S-2 9.78 DNMT3A HIP1 RUNX1 SRSF2 U2AF1

MGI Mouse Phenotypes related to Chronic Myelomonocytic Leukemia:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.55 ASXL1 CSF2 CSF3R DNMT3A ETV6 EZH2
2 hematopoietic system MP:0005397 10.5 ASXL1 CSF2 CSF3R DNMT3A ETV6 EZH2
3 endocrine/exocrine gland MP:0005379 10.47 ASXL1 CSF2 DNMT3A ETV6 EZH2 FLT3
4 growth/size/body region MP:0005378 10.46 ASXL1 CSF2 DNMT3A ETV6 EZH2 FLT3
5 immune system MP:0005387 10.45 ASXL1 CSF2 CSF3R DNMT3A ETV6 EZH2
6 mortality/aging MP:0010768 10.45 ASXL1 CSF2 CSF3R DNMT3A ETV6 EZH2
7 cardiovascular system MP:0005385 10.44 CSF2 DNMT3A ETV6 EZH2 GATA2 JAK2
8 homeostasis/metabolism MP:0005376 10.44 ASXL1 CSF2 DNMT3A ETV6 EZH2 FLT3
9 behavior/neurological MP:0005386 10.42 ASXL1 CSF2 CSF3R DNMT3A EZH2 HIP1
10 embryo MP:0005380 10.35 CSF2 DNMT3A ETV6 EZH2 GATA2 JAK2
11 neoplasm MP:0002006 10.25 ASXL1 CSF2 ETV6 EZH2 FLT3 HIP1
12 nervous system MP:0003631 10.18 CSF2 DNMT3A EZH2 GATA2 HIP1 KDM6A
13 integument MP:0010771 10.16 CSF2 ETV6 EZH2 JAK2 KIT NF1
14 liver/biliary system MP:0005370 10.15 ASXL1 GATA2 HIP1 JAK2 KIT NF1
15 craniofacial MP:0005382 10.13 ASXL1 CSF2 KDM6A KIT NF1 PDGFRB
16 muscle MP:0005369 10.11 DNMT3A EZH2 HIP1 KDM6A KIT NF1
17 normal MP:0002873 10.1 ETV6 EZH2 GATA2 HIP1 JAK2 KDM6A
18 no phenotypic analysis MP:0003012 9.97 ETV6 EZH2 FLT3 KDM6A KIT PTPN11
19 reproductive system MP:0005389 9.85 CSF2 DNMT3A GATA2 HIP1 JAK2 KDM6A
20 renal/urinary system MP:0005367 9.8 CSF2 EZH2 GATA2 KIT NF1 PDGFRB
21 respiratory system MP:0005388 9.61 CSF2 EZH2 HIP1 JAK2 KDM6A KIT
22 skeleton MP:0005390 9.44 ASXL1 CSF2 DNMT3A EZH2 FLT3 HIP1

Drugs & Therapeutics for Chronic Myelomonocytic Leukemia

Drugs for Chronic Myelomonocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 320)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
2
Mercaptopurine Approved Phase 3 50-44-2 667490
3
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
4
Ofloxacin Approved Phase 3 82419-36-1 4583
5
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
6
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
7
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
8
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
9
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
10
Idarubicin Approved Phase 3 58957-92-9 42890
11
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
12
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
13
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
14
Thioguanine Approved Phase 3 154-42-7 2723601
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
17
Dalteparin Approved Phase 3 9005-49-6
18
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
19
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
20
Acyclovir Approved Phase 3 59277-89-3 2022
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
22
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
23
Lenalidomide Approved Phase 3 191732-72-6 216326
24
Daunorubicin Approved Phase 3 20830-81-3 30323
25
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
26
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
27
tannic acid Approved Phase 3 1401-55-4
28
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
29
Hydroxyurea Approved Phase 3 127-07-1 3657
30
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
31
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
32
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
33
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
34
Polyestradiol phosphate Approved Phase 3 28014-46-2
35
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
36
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
37
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
38 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
39 Guadecitabine Investigational Phase 3 929901-49-5
40
Lonafarnib Investigational Phase 3 193275-84-2 148195
41 Anesthetics, Dissociative Phase 3
42 Analgesics, Non-Narcotic Phase 3
43 Interleukin-2 Phase 3
44 Analgesics Phase 3
45 Anti-HIV Agents Phase 3
46 Anti-Retroviral Agents Phase 3
47 Neurotransmitter Agents Phase 3
48 Adjuvants, Immunologic Phase 3
49 Antineoplastic Agents, Hormonal Phase 3
50 Anti-Anxiety Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 500)
# Name Status NCT ID Phase Drugs
1 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
2 Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Secondary (SAML) to MDS of More Acute Than 6 Months Duration Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
3 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
4 INDUCTION WITH ALL-TRANS RETINOIC ACID IN COMBINATION WITH IDARUBICIN AND INTENSIVE CONSOLIDATION FOLLOWED BY BONE MARROW TRANSPLANTATION OR A RANDOMIZED MAINTENANCE TREATMENT DEPENDING UPON THE AMOUNT OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA Unknown status NCT00002701 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;idarubicin;mercaptopurine;methotrexate;mitoxantrone hydrochloride;thioguanine;tretinoin
5 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
6 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 A Randomized, Open-label, Phase III Trial of Decitabine (5-aza-2'Deoxycytidine) Versus Supportive Care in Adults With Advanced-stage Myelodysplastic Syndrome Completed NCT00043381 Phase 3 decitabine (5-aza-2'deoxycytidine)
8 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
9 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
10 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML &lt; 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
11 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
12 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
13 A Phase III Randomized Study Comparing Busulfan-Total Body Irradiation Versus Cyclophosphamide-Total Body Irradiation Preparative Regimen in Patients With Advanced Myelodysplastic Syndrome (MDS) or MDS-Related Acute Myeloid Leukemia (AML) Undergoing HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation, (A BMT Study) Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
14 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
15 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
16 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
17 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
18 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
19 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
20 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
21 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
22 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
23 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
24 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
25 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
26 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
27 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
28 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
29 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
30 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
31 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
32 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
33 Randomized Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) Completed NCT00887068 Phase 3 Azacitidine
34 A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) Recruiting NCT04266301 Phase 3 MBG453;Azacitidine;Placebo
35 The Clinical Efficacy of Azacytidine Combined With HAG Regimen in Elderly Patients With Myeloid Malignancy Recruiting NCT03873311 Phase 3 Azacytidine, HAG Regimen
36 A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Recruiting NCT04256317 Phase 2, Phase 3 Azacitidine;ASTX030 (cedazuridine + azacitidine);Cedazuridine
37 A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia Active, not recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
38 A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) Active, not recruiting NCT03306264 Phase 3 ASTX727;Dacogen
39 Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
40 A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents Active, not recruiting NCT02907359 Phase 3 Guadecitabine
41 Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
42 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission Active, not recruiting NCT01757535 Phase 3 300 mg Oral Azacitidine;Placebo
43 Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid) Alone and in Combination With Epoetin Alfa (Procrit) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
44 A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) Active, not recruiting NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
45 A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML) Active, not recruiting NCT02214407 Phase 3 Decitabine;HYDROXYUREA
46 A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia Terminated NCT00109538 Phase 3 Lonafarnib
47 Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
48 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
49 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
50 Allogeneic Stem Cell Transplantation Using Mylotarg (CMA-676) Plus Nonmyeloablative Chemotherapy in Older or Medically Infirm Patients With High-Risk Acute Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or Myelodysplastic Syndrome (MDS) Terminated NCT00038805 Phase 2, Phase 3 Mylotarg

Search NIH Clinical Center for Chronic Myelomonocytic Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Myelomonocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Chronic Myelomonocytic Leukemia:
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Chronic Myelomonocytic Leukemia:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244

Genetic Tests for Chronic Myelomonocytic Leukemia

Genetic tests related to Chronic Myelomonocytic Leukemia:

# Genetic test Affiliating Genes
1 Chronic Myelomonocytic Leukemia 29

Anatomical Context for Chronic Myelomonocytic Leukemia

MalaCards organs/tissues related to Chronic Myelomonocytic Leukemia:

40
Myeloid, Bone, Bone Marrow, Monocytes, T Cells, Neutrophil, Skin

Publications for Chronic Myelomonocytic Leukemia

Articles related to Chronic Myelomonocytic Leukemia:

(show top 50) (show all 1628)
# Title Authors PMID Year
1
RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. 54 61
19282830 2009
2
Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways. 61 54
19100521 2009
3
Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. 54 61
18555525 2008
4
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. 54 61
18925961 2008
5
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. 54 61
18055864 2008
6
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. 61 54
17936561 2007
7
The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. 61 54
17643100 2007
8
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. 61 54
16955510 2006
9
Atypical myeloproliferative disorders: diagnosis and management. 54 61
16610578 2006
10
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. 54 61
16037387 2005
11
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. 54 61
15725481 2005
12
Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. 54 61
15995322 2005
13
Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. 61 54
15068895 2004
14
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. 61 54
12908555 2003
15
Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo. 61 54
12384142 2002
16
Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. 61 54
11588050 2001
17
Regulation of the Src homology 2-containing inositol 5-phosphatase SHIP1 in HIP1/PDGFbeta R-transformed cells. 61 54
11287412 2001
18
Tyrosine phosphorylation of proteins in primary human myeloid leukemic cells stimulated by macrophage colony-stimulating factor: analysis by disease type and comparison with normal human hematopoietic cells. 61 54
11372744 2001
19
Protease inhibitor 10 inhibits tumor necrosis factor alpha -induced cell death. Evidence for the formation of intracellular high M(r) protease inhibitor 10-containing complexes. 54 61
10871600 2000
20
Thrombopoietin and myelodysplastic syndromes. 61 54
11039665 2000
21
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. 61 54
11105617 2000
22
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. 54 61
10784392 2000
23
Priming effects of macrophage colony-stimulating factor on monocytic leukemia cells in combination with chemotherapy: induction of programmed cell death in vivo. 54 61
10784404 2000
24
Transforming properties of the Huntingtin interacting protein 1/ platelet-derived growth factor beta receptor fusion protein. 61 54
10428802 1999
25
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. 61 54
9834234 1998
26
Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). 54 61
9616134 1998
27
Myc is essential for transformation by TEL/platelet-derived growth factor receptor beta (PDGFRbeta). 61 54
9558390 1998
28
Analysis of the granulocyte colony-stimulating factor receptor gene structure using PCR-SSCP in myeloid leukemia and myelodysplastic syndrome. 54 61
9548419 1998
29
Expression of bomapin, a novel human serpin, in normal/malignant hematopoiesis and in the monocytic cell lines THP-1 and AML-193. 61 54
9454755 1998
30
Feasibility of peripheral blood stem cell (PBSC) and peripheral blood mononuclear cell (PBMNC) separation in children with a body weight below 20 KG. 61 54
9180913 1997
31
Prolonged extreme thrombocytosis associated with neurofibromatosis type 1. 61 54
9042140 1997
32
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. 61 54
8962143 1996
33
The effects of thrombopoietin on the growth of acute myeloblastic leukemia cells. 61 54
9031083 1996
34
ETV6 gene rearrangements in hematopoietic malignant disorders. 54 61
9031109 1996
35
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. 54 61
8839838 1996
36
Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells. 61 54
8879210 1996
37
Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. 54 61
8751457 1996
38
Lymphoblastic transformation of chronic myelomonocytic leukemia in an infant. 61 54
8756090 1996
39
In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels. 61 54
9816264 1996
40
bcr gene rearrangement analysis in myeloproliferative disorders other than chronic myelogenous leukemia. 54 61
8818385 1996
41
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. 61 54
7479840 1995
42
The levels of granulocyte colony-stimulating factor in the plasma of the bone marrow aspirate in various hematological disorders. 61 54
7549901 1995
43
Exon trap analysis of a NF1 splice-site mutation in a chronic myelomonocytic leukemia patient. 54 61
7769857 1995
44
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. 54 61
7761424 1995
45
Prognostic value of c-mpl expression in myelodysplastic syndromes. 61 54
7539513 1995
46
c-mpl expression in hematologic disorders. 54 61
7773160 1995
47
Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. 61 54
8049440 1994
48
Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome. 54 61
7514248 1994
49
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. 54 61
8168137 1994
50
Selective involvement of monocytes by acquired myeloperoxidase deficiency in a case of chronic myelomonocytic leukemia. 54 61
8389605 1993

Variations for Chronic Myelomonocytic Leukemia

ClinVar genetic disease variations for Chronic Myelomonocytic Leukemia:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ETV6 , FLT3 t(12;13)(p13.2;q12.2)Translocation Likely pathogenic 590266 12:12037520-12037521

Copy number variations for Chronic Myelomonocytic Leukemia from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 160282 22 11800000 24300000 Translocation Chronic myelomonocytic leukemia
2 228217 7 75001344 75206215 Translate HIP1 Chronic myelomonocytic leukemia
3 247204 9 129300000 140273252 Translocation Chronic myelomonocytic leukemia

Expression for Chronic Myelomonocytic Leukemia

Search GEO for disease gene expression data for Chronic Myelomonocytic Leukemia.

Pathways for Chronic Myelomonocytic Leukemia

Pathways related to Chronic Myelomonocytic Leukemia according to KEGG:

36
# Name Kegg Source Accession
1 Ras signaling pathway hsa04014

Pathways related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.32 PTPN11 PDGFRB NF1 KIT KDM6A JAK2
2
Show member pathways
13.08 PTPN11 PDGFRB NF1 KIT JAK2 FLT3
3
Show member pathways
12.66 RUNX1 PTPN11 PDGFRB KIT FLT3 CSF2
4
Show member pathways
12.58 PTPN11 PDGFRB NF1 KIT FLT3
5 12.52 RUNX1 PDGFRB KIT JAK2 FLT3 CSF3R
6 12.28 TET2 KDM6A EZH2 DNMT3A
7
Show member pathways
12.27 PTPN11 PDGFRB JAK2 CSF3R CSF2
8 11.93 PDGFRB KIT JAK2 FLT3
9
Show member pathways
11.66 PDGFRB KIT FLT3
10 11.62 KIT FLT3 CSF3R CSF2
11 11.6 KIT FLT3 CSF2
12 11.57 PDGFRB KIT FLT3
13 11.49 TET2 NF1 EZH2
14 11.45 KIT FLT3 CSF3R CSF2
15 11.35 RUNX1 GATA2 CSF2
16 11.3 RUNX1 KDM6A FLT3 ETV6 CSF2
17
Show member pathways
11.11 PDGFRB KIT FLT3
18 10.47 FLT3 ETV6 DNMT3A

GO Terms for Chronic Myelomonocytic Leukemia

Cellular components related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.9 U2AF1 SRSF2 SETBP1 RUNX1 PTPN11 KDM6A
2 nucleus GO:0005634 9.55 U2AF1 TET2 SRSF2 SETBP1 RUNX1 PTPN11
3 receptor complex GO:0043235 9.26 PDGFRB KIT FLT3 CSF3R

Biological processes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 PDGFRB KIT JAK2 FLT3 EZH2 CSF2
2 regulation of gene expression GO:0010468 9.92 NF1 KDM6A EZH2 DNMT3A CSF2
3 regulation of cell proliferation GO:0042127 9.87 NF1 KIT EZH2 CSF2
4 positive regulation of protein kinase B signaling GO:0051897 9.85 PTPN11 PDGFRB KIT HIP1
5 chromatin organization GO:0006325 9.85 TET2 KDM6A JAK2 EZH2 DNMT3A ASXL1
6 protein autophosphorylation GO:0046777 9.84 PDGFRB KIT JAK2 FLT3
7 peptidyl-tyrosine phosphorylation GO:0018108 9.81 PDGFRB KIT JAK2 FLT3
8 positive regulation of kinase activity GO:0033674 9.77 PDGFRB KIT FLT3
9 hematopoietic progenitor cell differentiation GO:0002244 9.76 PDGFRB KIT FLT3
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.73 PDGFRB KIT JAK2 FLT3
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 KIT JAK2 FLT3 CSF2
12 platelet-derived growth factor receptor signaling pathway GO:0048008 9.65 PTPN11 PDGFRB JAK2
13 megakaryocyte development GO:0035855 9.63 PTPN11 KIT
14 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.63 PDGFRB KIT FLT3
15 cytokine-mediated signaling pathway GO:0019221 9.63 PTPN11 KIT JAK2 FLT3 CSF3R CSF2
16 hematopoietic stem cell proliferation GO:0071425 9.62 RUNX1 ETV6
17 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.62 PDGFRB JAK2
18 positive regulation of MAP kinase activity GO:0043406 9.62 PDGFRB KIT FLT3 EZH2
19 dendritic cell differentiation GO:0097028 9.61 FLT3 CSF2
20 smooth muscle tissue development GO:0048745 9.61 PDGFRB NF1
21 positive regulation of phospholipase C activity GO:0010863 9.6 PDGFRB KIT
22 response to fluid shear stress GO:0034405 9.58 PDGFRB CSF2
23 myeloid progenitor cell differentiation GO:0002318 9.56 KIT FLT3
24 regulation of myeloid cell differentiation GO:0045637 9.43 RUNX1 CSF3R CSF2
25 MAPK cascade GO:0000165 9.43 PDGFRB NF1 KIT JAK2 FLT3 CSF2
26 hemopoiesis GO:0030097 9.02 RUNX1 KIT GATA2 FLT3 ASXL1

Molecular functions related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.77 KDM6A GATA2 EZH2 DNMT3A ASXL1
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.63 RUNX1 KDM6A GATA2 EZH2 ETV6 DNMT3A
3 protein binding GO:0005515 9.62 U2AF1 TET2 SRSF2 SETBP1 RUNX1 PTPN11
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.5 PDGFRB KIT FLT3
5 insulin receptor substrate binding GO:0043560 9.43 PTPN11 JAK2
6 growth factor binding GO:0019838 9.43 PDGFRB KIT FLT3
7 peptide hormone receptor binding GO:0051428 9.4 PTPN11 JAK2
8 protein tyrosine kinase activity GO:0004713 9.26 PDGFRB KIT JAK2 FLT3

Sources for Chronic Myelomonocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....